The latest research news relevant to pharmacy, compiled by Debbie Rigby
Varenicline is the most effective monotherapy treatment for tobacco dependence. The effectiveness of varenicline can be improved by taking it in combination with other medications, enhancing patient adherence and extending the duration of treatment. Varenicline is considered safe and effective in treating tobacco dependence among people who are at higher risk for neuropsychiatric symptoms and cardiovascular disease.
Patient Preference and Adherence 2016:10 435–441.
The incidence of Clostridium difficile infection (CDI) continues to rise, whilst treatment remains problematic due to recurrent, refractory and potentially severe nature of disease. These updated guidelines recommend treatment protocols for adults and children. Oral metronidazole is recommended for initial episode CDI without clinical features of severe disease at 400 mg three times daily for 10 days.
Internal Medical Journal 2016.
A systematic literature search of RCTs has shown no evidence to support the routine use of omega-3 PUFAs in the primary and secondary prevention of CVD. Two meta-analyses concluded omega-3 PUFAs do not reduce CV events in addition to standard, evidence-based therapy in patients after myocardial infarction. Omega-3 PUFAs can increase the risk of bleeding and may interact with other medications that affect hemostasis, such as antiplatelet agents and warfarin.
Canadian Pharmacists Journal. April 4, 2016
A double-blind randomised trial of 376 patients aged 18 years or older comapred the effectiveness and safety of oral prednisolone versus oral indomethacin for acute gout. Oral prednisolone and indomethacin had similar analgesic effectiveness among patients with acute gout. The authors concluded that prednisolone is a safe, effective first-line option for treatment of acute gout.
Ann Intern Med. 2016;164(7):464-471.